Novartis is buying a breast cancer drug candidate from Delaware-based Synnovation Therapeutics. The transaction is worth $2 billion. With this, Novartis wants to strengthen its development pipeline. It is an experimental drug intended for the treatment of breast cancer. This step is part of the company's strategy to expand the portfolio of oncology preparations.